A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Luo, Jian ^a   Swaminath, Gayathri ^a   Brown, Sean P ^a   Zhang, Jane ^a   Guo, Qi ^a   Chen, Michael ^a   Nguyen, Kathy ^a   Tran, Thanhvien ^a   Miao, Lynn ^a   Dransfield, Paul J ^a   Vimolratana, Marc ^a   Houze, Jonathan B ^a   Wong, Simon ^a   Toteva, Maria ^a   Shan, Bei ^a   Li, Frank ^a   Zhuang, Run ^a   Lin, Daniel C H ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AM 1638; AM 6226; AMG 837; ANTIDIABETIC AGENT; G PROTEIN COUPLED RECEPTOR 40; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIARRHEAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG POTENCY; DRUG STRUCTURE; ENTEROENDOCRINE CELL; GLUCOSE HOMEOSTASIS; HYPERGLYCEMIA; LIPID DIET; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PROTEIN SECRETION; RODENT; SINGLE DRUG DOSE; STRUCTURE ANALYSIS;

ANIMALS; BLOOD GLUCOSE; CHO CELLS; CRICETINAE; CRICETULUS; INSULIN; MICE; MICE, KNOCKOUT; RECEPTORS, G-PROTEIN-COUPLED; SECOND MESSENGER SYSTEMS;

EID: 84867290314     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046300     Document Type: Article

References (44)

1. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, et al. (2003) Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422: 173-176.
2. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, et al. (2003) The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278: 11303-11311.
3. Edfalk S, Steneberg P, Edlund H, (2008) Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57: 2280-2287.
4. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F, (2009) Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52: 289-298.
5. Tomita T, Masuzaki H, Noguchi M, Iwakura H, Fujikura J, et al. (2005) GPR40 gene expression in human pancreas and insulinoma. Biochem Biophys Res Commun 338: 1788-1790.
6. Davidson JA, (2010) Incorporating incretin-based therapies into clinical practice: differences between glucagon-like Peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 85: S27-37.
7. Peters A, (2010) Incretin-based therapies: review of current clinical trial data. Am J Med 123: S28-37.
8. Hara T, Hirasawa A, Ichimura A, Kimura I, Tsujimoto G, (2011) Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J Pharm Sci 100: 3594-3601.
9. Telvekar VN, Kundaikar HS, (2008) GPR40 carboxylic acid receptor family and diabetes: a new drug target. Curr Drug Targets 9: 899-910.
10. Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, et al. (2007) GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56: 1087-1094.
11. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, et al. (2008) The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57: 2432-2437.
12. Alquier T, Peyot ML, Latour MG, Kebede M, Sorensen CM, et al. (2009) Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58: 2607-2615.
13. Vettor R, Granzotto M, De Stefani D, Trevellin E, Rossato M, et al. (2008) Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J Clin Endocrinol Metab 93: 3541-3550.
14. Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, et al. (2008) Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57: 2211-2219.
15. Tikhonova IG, Sum CS, Neumann S, Engel S, Raaka BM, et al. (2008) Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J Med Chem 51: 625-633.
16. Negoro N, Sasaki S, Mikami S, Ito M, Suzuki M, et al. (2010) Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist. ACS Medicinal Chemistry Letters 1: 290-294.
17. Lin DC, Zhang J, Zhuang R, Li F, Nguyen K, et al. (2011) AMG 837: A Novel GPR40/FFA1 Agonist that Enhances Insulin Secretion and Lowers Glucose Levels in Rodents. PLoS One 6: e27270.
18. Houze JB, Zhu L, Sun Y, Akerman M, Qiu W, et al. (2012) AMG 837: a potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett 22: 1267-1270.
19. Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, et al. (2012) Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 52: 1007-1016.
20. Araki T, Hirayama M, Hiroi S, Kaku K (2011) GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab.
21. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, et al. (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet.
22. Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, et al. (2006) Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 148: 619-628.
23. Christiansen E, Urban C, Merten N, Liebscher K, Karlsen KK, et al. (2008) Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem 51: 7061-7064.
24. Lin D, Guo Q, Luo J, Zhang J, Nguyen K, et al. (2012) Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the FFA1 Receptor. Mol Pharmacol.
25. Drucker DJ, Nauck MA, (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 1696-1705.
26. Brubaker PL, Vranic M, (1987) Fetal rat intestinal cells in monolayer culture: a new in vitro system to study the glucagon-like immunoreactive peptides. Endocrinology 120: 1976-1985.
27. Iakoubov R, Izzo A, Yeung A, Whiteside CI, Brubaker PL, (2007) Protein kinase Czeta is required for oleic acid-induced secretion of glucagon-like peptide-1 by intestinal endocrine L cells. Endocrinology 148: 1089-1098.
28. Brown SP, Dransfield PJ, Vimolratana M, Jiao X, Zhu L, et al. (2012) Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist. ACS Medicinal Chemistry Letters.
29. Luo J, Quan J, Tsai J, Hobensack CK, Sullivan C, et al. (1998) Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 47: 663-668.
30. Cho YR, Kim HJ, Park SY, Ko HJ, Hong EG, et al. (2007) Hyperglycemia, maturity-onset obesity, and insulin resistance in NONcNZO10/LtJ males, a new mouse model of type 2 diabetes. Am J Physiol Endocrinol Metab 293: E327-336.
31. Leiter EH, Reifsnyder PC, Zhang W, Pan HJ, Xiao Q, et al. (2006) Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes. Endocrinology 147: 919-926.
32. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, et al. (2005) (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48: 141-151.
33. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, et al. (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11: 90-94.
34. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, et al. (2012) Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483: 350-354.
35. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, et al. (1993) Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 268: 19650-19655.
36. Thorens B, Porret A, Buhler L, Deng SP, Morel P, et al. (1993) Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 42: 1678-1682.
37. Mundil D, Cameron-Vendrig A, Husain M, (2012) GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diab Vasc Dis Res 9: 95-108.
38. Liou AP, Lu X, Sei Y, Zhao X, Pechhold S, et al. (2011) The G-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 140: 903-912.
39. Sykaras AG, Demenis C, Case RM, McLaughlin JT, Smith CP, (2012) Duodenal Enteroendocrine I-Cells Contain mRNA Transcripts Encoding Key Endocannabinoid and Fatty Acid Receptors. PLoS One 7: e42373.
40. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, et al. (2011) TAK-875, an Orally Available GPR40/FFA1 Agonist Enhances Glucose-Dependent Insulin Secretion and Improves Both Postprandial and Fasting Hyperglycemia in Type 2 Diabetic Rats. J Pharmacol Exp Ther.
41. Alquier T, Poitout V, (2009) GPR40: good cop, bad cop? Diabetes 58: 1035-1036.
42. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H, (2005) The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab 1: 245-258.
43. Nagasumi K, Esaki R, Iwachidow K, Yasuhara Y, Ogi K, et al. (2009) Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58: 1067-1076.
44. Smith NJ, Bennett KA, Milligan G, (2011) When simple agonism is not enough: emerging modalities of GPCR ligands. Mol Cell Endocrinol 331: 241-247.